Pharmacokinetics articles within Nature Communications

Featured

  • Article
    | Open Access

    Combination therapies simultaneously inhibiting different therapeutic targets in cancer is challenged by individual pharmacokinetic profiles. Here, the authors generate an orally provided multi-targeted kinase inhibitor that is lymphatic absorbed and increases survival in a murine model of myelofibrosis.

    • Brian D. Ross
    • , Youngsoon Jang
    •  & Marcian E. Van Dort

  • Article
    | Open Access

    It is currently difficult to synthesise NIR-II probes with good quantum yields, biocompatibility and pharmacokinetics. Here the authors report a strategy to alter these properties by modifying the protein coatings with biofunctional molecules, and generate long-wavelength fluorophores for in vivo imaging.

    • Rui Tian
    • , Xin Feng
    •  & Xiaoyuan Chen

  • Article
    | Open Access

    Understanding the pharmacokinetics of locally-injected drugs could aid in the design of immunotherapies to maximize their therapeutic effect. Here, by evaluating different IL-2 fusion proteins, the authors show that molecular weight and matrix binding affect anti-tumor immune response and report a pharmacokinetic framework to predict response to intratumoral IL-2 therapy.

    • Noor Momin
    • , Joseph R. Palmeri
    •  & K. Dane Wittrup

  • Article
    | Open Access

    Mutations in ryanodine receptor 1 (RyR1), a Ca2+ release channel in skeletal muscle, cause malignant hyperthermia (MH) and are involved in heat stroke. Here, the authors show that an oxolinic acid-derivative RyR1 inhibitor effectively prevents and treats MH and heat stroke in various MH mouse models.

    • Toshiko Yamazawa
    • , Takuya Kobayashi
    •  & Takashi Murayama

  • Article
    | Open Access

    Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly drug administration.

    • Brady Sillman
    • , Aditya N. Bade
    •  & Howard E. Gendelman

  • Article
    | Open Access

    Traditional approaches used in the pharmaceutical industry are not precise or versatile enough for customized medicine formulation and manufacture. Here the authors produce a method to form coatings, with accurate dosages, as well as a means of closely controlling dissolution kinetics.

    • Olga Shalev
    • , Shreya Raghavan
    •  & Max Shtein

  • Article
    | Open Access

    Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

    • Dirk Roymans
    • , Sarhad S Alnajjar
    •  & Anil Koul

  • Article
    | Open Access

    Drug molecules operate through physical interaction with specific cellular targets, and understanding this interaction is important for mechanisms and the potential therapeutic effect of drug candidates. Here, the authors show that bioluminescence resonance energy transfer can be used to monitor the intracellular engagement of a drug with its target.

    • Matthew B. Robers
    • , Melanie L. Dart
    •  & Keith V. Wood

  • Article
    | Open Access

    Tuberculosis control is threatened by the continued emergence of drug-resistant strains. Here, Rybniker et al. screen a library of FDA-approved drugs and identify a gastric proton pump inhibitor that also has antituberculosis activity and targets the bacterial cytochrome bc1complex.

    • Jan Rybniker
    • , Anthony Vocat
    •  & Stewart T. Cole

  • Article |

    Central to the lineage commitment of multipotent mesenchymal stem cells is the nuclear receptor PPARγ, the master regulator of adipogenesis. Here the authors use a variety of structural approaches to rationally design PPARγ inverse agonist SR2595, and demonstrate its ability to promote osteogenesis.

    • David P. Marciano
    • , Dana S. Kuruvilla
    •  & Patrick R. Griffin

  • Article |

    Current pharmacokinetic models describe the distribution of drugs within tissues but usually lack single-cell resolution. Here Weissleder and colleagues visualize the subcellular distribution of an anticancer drug in real time in living animals and develop a model to extrapolate these findings to humans.

    • Greg M. Thurber
    • , Katy S. Yang
    •  & Ralph Weissleder

Browse broader subjects

Browse Pharmacokinetics across other nature.com journals